Current and historical daily PE Ratio for Interpace Biosciences Inc (
) from 2016 to Jun 06 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Interpace Biosciences stock (STU:PF42) PE ratio as of Jun 06 2024 is 4.51.
More Details
Interpace Biosciences Inc (STU:PF42) PE Ratio (TTM) Chart
Interpace Biosciences Inc (STU:PF42) PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
Total 1256
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Interpace Biosciences PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-06 | 4.1 | 2024-04-03 | 4.1 |
| 2024-06-05 | 4.1 | 2024-04-02 | 3.8 |
| 2024-06-04 | 4.2 | 2024-03-28 | 4.2 |
| 2024-06-03 | 3.5 | 2024-03-27 | 4.6 |
| 2024-05-31 | 3.5 | 2024-03-26 | 4.6 |
| 2024-05-30 | 3.9 | 2024-03-25 | 4.8 |
| 2024-05-29 | 4.0 | 2024-03-22 | 4.8 |
| 2024-05-28 | 3.8 | 2024-03-21 | 4.8 |
| 2024-05-27 | 3.8 | 2024-03-20 | 4.3 |
| 2024-05-24 | 3.8 | 2024-03-19 | 4.5 |
| 2024-05-23 | 3.8 | 2024-03-18 | 4.5 |
| 2024-05-22 | 3.8 | 2024-03-15 | 4.8 |
| 2024-05-21 | 3.8 | 2024-03-14 | 4.8 |
| 2024-05-20 | 3.8 | 2024-03-13 | 4.8 |
| 2024-05-17 | 3.7 | 2024-03-12 | 5.0 |
| 2024-05-16 | 3.6 | 2024-03-11 | 4.8 |
| 2024-05-15 | 3.7 | 2024-03-08 | 5.1 |
| 2024-05-14 | 4.0 | 2024-03-07 | 5.0 |
| 2024-05-13 | 4.0 | 2024-03-06 | 3.2 |
| 2024-05-10 | 3.8 | 2024-03-05 | 3.1 |
| 2024-05-09 | 3.8 | 2024-03-04 | 3.0 |
| 2024-05-08 | 3.8 | 2024-03-01 | 3.1 |
| 2024-05-07 | 3.8 | 2024-02-29 | 3.2 |
| 2024-05-06 | 3.8 | 2024-02-28 | 3.1 |
| 2024-05-03 | 3.8 | 2024-02-27 | 3.1 |
| 2024-05-02 | 3.8 | 2024-02-26 | 3.2 |
| 2024-04-30 | 3.9 | 2024-02-23 | 3.0 |
| 2024-04-29 | 3.7 | 2024-02-22 | 3.1 |
| 2024-04-26 | 4.2 | 2024-02-21 | 3.1 |
| 2024-04-25 | 3.7 | 2024-02-20 | 3.0 |
| 2024-04-24 | 4.0 | 2024-02-19 | 3.0 |
| 2024-04-23 | 4.0 | 2024-02-16 | 3.0 |
| 2024-04-22 | 4.0 | 2024-02-15 | 3.0 |
| 2024-04-19 | 4.0 | 2024-02-14 | 2.9 |
| 2024-04-18 | 4.0 | 2024-02-13 | 2.6 |
| 2024-04-17 | 4.0 | 2024-02-12 | 2.7 |
| 2024-04-16 | 4.1 | 2024-02-09 | 2.9 |
| 2024-04-15 | 3.8 | 2024-02-08 | 2.9 |
| 2024-04-12 | 4.0 | 2024-02-07 | 3.0 |
| 2024-04-11 | 3.8 | 2024-02-06 | 3.0 |
| 2024-04-10 | 4.1 | 2024-02-05 | 3.1 |
| 2024-04-09 | 3.8 | 2024-02-02 | 3.0 |
| 2024-04-08 | 3.8 | 2024-02-01 | 3.0 |
| 2024-04-05 | 3.9 | 2024-01-31 | 3.0 |
| 2024-04-04 | 3.8 | 2024-01-30 | 3.0 |
Interpace Biosciences Inc (STU:PF42) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Interpace Biosciences Inc
NAICS : 541380
SIC : 8099
ISIN : US46062X2045
Description
Interpace Biosciences Inc is a fully integrated commercial company. It provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first line assays principally focused on early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers